These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12820341)

  • 1. Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer.
    Lüftner D; Richter A; Geppert R; Wernecke KD; Possinger K
    Anticancer Res; 2003; 23(2A):1017-26. PubMed ID: 12820341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The course of the urinary DPD-crosslink secretion in metastatic breast cancer--a possibility for response assessment.
    Lüftner D; Günther S; Flath B; Müller C; Echteroff K; Mergenthaler HG; Wernecke KD; Possinger K
    Anticancer Res; 1999; 19(4A):2537-44. PubMed ID: 10470191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer.
    Lüfter D; Richter A; Günther S; Flath B; Akrivakis C; Geppert R; Wernecke KD; Possinger K
    Anticancer Res; 2000; 20(6D):5099-105. PubMed ID: 11326676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
    Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
    Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
    Vinholes J; Coleman R; Lacombe D; Rose C; Tubiana-Hulin M; Bastit P; Wildiers J; Michel J; Leonard R; Nortier J; Mignolet F; Ford J
    Br J Cancer; 1999 Apr; 80(1-2):221-8. PubMed ID: 10390000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
    Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
    J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
    Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
    Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
    DeLaurier A; Jackson B; Pfeiffer D; Ingham K; Horton MA; Price JS
    Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cross-sectional study of bone turnover markers in healthy premenopausal women.
    de Papp AE; Bone HG; Caulfield MP; Kagan R; Buinewicz A; Chen E; Rosenberg E; Reitz RE
    Bone; 2007 May; 40(5):1222-30. PubMed ID: 17331821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.
    Oremek G; Sauer-Eppel H; Klepzig M
    Anticancer Res; 2007; 27(4A):1961-2. PubMed ID: 17649805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
    Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases].
    Li SF; Wang XR; Wang C; Chen Y; Ren L; Cui L; Tong ZS
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):911-5. PubMed ID: 20193330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
    Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
    Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
    J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.